1. Academic Validation
  2. The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target

The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target

  • Clin Cancer Res. 2017 Feb 15;23(4):885-893. doi: 10.1158/1078-0432.CCR-16-2071.
Mariano G Cardenas 1 Erin Oswald 1 Wenbo Yu 2 Fengtian Xue 2 Alexander D MacKerell Jr 2 Ari M Melnick 3
Affiliations

Affiliations

  • 1 Department of Hematology/Oncology, Weill Cornell Medicine, New York, New York.
  • 2 Department of Pharmaceutical Sciences, Computer-Aided Drug Design Center, School of Pharmacy, University of Maryland, Baltimore, Maryland.
  • 3 Department of Hematology/Oncology, Weill Cornell Medicine, New York, New York. amm2014@med.cornell.edu.
Abstract

BCL6 was initially discovered as an oncogene in B-cell lymphomas, where it drives the malignant phenotype by repressing proliferation and DNA damage checkpoints and blocking B-cell terminal differentiation. BCL6 mediates its effects by binding to hundreds of target genes and then repressing these genes by recruiting several different chromatin-modifying corepressor complexes. Structural characterization of BCL6-corepressor complexes suggested that BCL6 might be a druggable target. Accordingly, a number of compounds have been designed to bind to BCL6 and block corepressor recruitment. These compounds, based on peptide or small-molecule scaffolds, can potently block BCL6 repression of target genes and kill lymphoma cells. In the case of diffuse large B-cell lymphomas (DLBCL), BCL6 inhibitors are equally effective in suppressing both the germinal center B-cell (GCB)- and the more aggressive activated B-cell (ABC)-DLBCL subtypes, both of which require BCL6 to maintain their survival. In addition, BCL6 is implicated in an expanding scope of hematologic and solid tumors. These include, but are not limited to, B-acute lymphoblastic leukemia, chronic myeloid leukemia, breast Cancer, and non-small cell lung Cancer. BCL6 inhibitors have been shown to exert potent effects against these tumor types. Moreover, mechanism-based combinations of BCL6 inhibitors with Other agents have yielded synergistic and often quite dramatic activity. Hence, there is a compelling case to accelerate the development of BCL6-targeted therapies for translation to the clinical setting. Clin Cancer Res; 23(4); 885-93. ©2016 AACR.

Figures
我们的 Cookie 政策

我们使用 Cookies 和类似技术以提高网站的性能和提升您的浏览体验,部分功能也使用 Cookies 帮助我们更好地理解您的需求,为您提供相关的服务。 如果您有任何关于我们如何处理您个人信息的疑问,请阅读我们的《隐私声明》